Filter
2806
Filtered Results: 2806
Text search:
Centers
of
Disease
Control
CDC
Featured
Recommendations
297
New Publications
725
Language
Document type
No document type
1495
Guidelines
438
Studies & Reports
336
Manuals
143
Fact sheets
133
Strategic & Response Plan
103
Training Material
54
Infographics
33
Situation Updates
24
Resource Platforms
23
Brochures
14
Online Courses
6
Dashboards/Maps
2
Videos
2
Countries / Regions
Global
110
Africa
104
Sierra Leone
102
Liberia
93
Nigeria
77
India
75
Ethiopia
73
West and Central Africa
71
Kenya
70
Congo, Democratic Republic of
62
East and Southern Africa
58
Guinea
55
Middle East and North Africa
54
Senegal
50
Uganda
50
Rwanda
47
Ghana
40
Western and Central Europe
40
Tanzania
39
Mozambique
39
Zambia
38
Latin America and the Carribbean
38
South Africa
35
Malawi
35
Haiti
34
Burkina Faso
33
Namibia
33
Côte d’Ivoire / Ivory Coast
29
Guinea-Bissau
28
South Sudan
28
Mali
26
Bangladesh
26
Russia
25
Cameroon
24
Syria
24
Brazil
24
Zimbabwe
22
Cambodia
21
Nepal
20
Germany
20
Yemen
20
USA
19
Colombia
19
Angola
19
Niger
18
Chad
18
Ukraine
18
Madagascar
16
Eastern Europe
14
Philippines
12
Indonesia
12
Asia
12
Botswana
10
Eastern Europe and Central Asia
10
Vietnam
10
Eswatini/ Swaziland
9
Lesotho
9
Myanmar / Burma
8
South–East Asia Region
8
Paraguay
8
Ecuador
7
Pakistan
6
Togo
5
Benin
5
Venezuela
5
France
5
Afghanistan
4
Egypt
4
Thailand
4
Chile
4
Western Pacific Region
4
Laos
4
North America
4
Spain
4
Saudi Arabia
3
Gambia
3
China
3
Sudan
3
Peru
3
Portugal
3
Somalia
2
Lebanon
2
Turkey
2
Central African Republic
2
Argentina
2
Burundi
2
Bolivia
2
Mexico
2
Congo-Brazzaville
2
Timor Leste/ East Timor
2
Gabon
2
Jamaica
2
Mauritius
2
Tunisia
2
Morocco
1
Iraq
1
Malaysia
1
Dominican Republic
1
Honduras
1
Cape Verde
1
Sri Lanka
1
Bhutan
1
Palestine
1
Italy
1
Albania
1
Armenia
1
Southern Africa
1
Tajikistan
1
Qatar
1
Kyrgyzstan
1
Australia
1
Kazakhstan
1
Uruguay
1
Japan
1
Belgium
1
United Kingdom
1
South Korea
1
Morocco
1
Authors & Publishers
Publication Years
Category
Countries
1067
Clinical Guidelines
233
Public Health
144
Key Resources
126
Women & Child Health
81
Pharmacy & Technologies
46
Capacity Building
40
Toolboxes
COVID-19
472
Ebola
232
HIV
217
TB
202
Rapid Response
156
AMR
146
NTDs
79
Zika
76
NCDs
69
Mental Health
65
Caregiver
49
Planetary Health
49
Cholera
41
Refugee
32
Specific Hazards
30
Polio
28
Pharmacy
26
Natural Hazards
25
Disability
19
Global Health Education
18
Conflict
15
Health Financing Toolbox
12
Social Ethics
1
April 2022 Volume 35 Issue 2 e00152-21
Population movements have turned Chagas disease (CD) into a global public health problem. Despite the successful implementation of subregional initiatives to...
These guidelines provide recommendations for the non-pharmacological aspects of infection prevention and control for acute respiratory diseases (AR...
Noncommunicable diseases (NCDs) such as cancer, cardiovascular disease, diabetes and chronic respiratory diseases and their risk factors are an inc...
Noncommunicable diseases (NCDs) such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are...
The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance deve...
This project aimed to reduce the risk of vector-borne infection with Chagas disease by
controlling triatomine bugs, the vectors transmitting the parasite ... Chagas disease, and
establishing an epidemiological surveillance system with community participation.
The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological
situation of the COVID-19 pandemic as ... 21 January 2022 – at a time when the Omicron VOC had been identified in 171
countries across all six WHO Regions and was rapidly replacing Delta worldwide – was considered Omicron has a substantial growth advantage, higher secondary attack rates and a higher observed reproduction number than Delta.
There is now significant evidence that immune evasion contributes to the rapid spread of Omicron. Other factors may be a shorter
serial interval (by about 0.8 to 1.2 days compared to Delta) and potential increased intrinsic transmission fitness . There is
growing evidence that with Omicron, there is lower vaccine effectiveness (VE) against infection and symptomatic disease soon after vaccination compared to Delta. There is also evidence of accelerated waning of VE over time of the primary series against infection and symptomatic disease for the studied vaccines. Further studies are required to better understand the drivers of transmission and declining incidence in various settings. These factors include the intrinsic transmission fitness properties of the virus, degree of immune evasion, vaccination coverage and level of vaccine-derived and post-infection immunity, levels of social mixing and degree of application of public health and social measures (PHSM).
The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance deve...
This article summarises the process involved in developing the updated guideline and includes an infographic to highlight key IPC recommendations from the guideline, following the patient care pathway from the community to a healthcare facility to discharge.
22 April 2022, This document provides updated interim recommendations on the use of masks by health workers providing care to patients with suspected or confirmed COVID-19. This update is prompted by new evidence around mask use and COVID-19 transmi...
. Interim Guidelines. This interim guideline lays out some basic principles of optimal nutritional care for adults and paediatric patients during treatment and convalescence in Ebola treatment units, community care ... or to other centres where Ebola patients are receiving care and support. It highlights the key clinical problems in patients affected by Ebola virus disease (EVD) that may interfere with their nutritional status and overall clinical support in the context of the current Ebola crisis, and summarizes their nutritional needs. It does not provide specific advice on fluid management in cases of vomiting, diarrhoea and dehydration or parenteral nutrition
To guide One Health capacity building efforts in the Republic of Guinea in the wake of the 2014–2016 Ebola virus disease (EVD) outbreak, we sough...
Asthma is a common breathing condition that affects 20% of all children Asthma tends to run in families, although this is not always the case. You may have seen someone at school who uses an inhaler to help them breathe better and ... asthma symptoms.
PEPFAR Malawi’s Country Operational Plan (COP) 2021 reflects a culmination of strong interagency collaboration between the PEPFAR Malawi team, Government of Malawi (GoM), and civil society organiz...
A tutorial for trainers in healthcare settings
Version 2: 2 Dec 2014
"The document focuses on an extended set of PPE components, which includes goggles, respirators, gloves,
coveralls and footwear. Used properly, these PPE components can provide ...
The "Global NCD action plan" provides a road map and a menu of policy options for countries to take in order to attain the 9 voluntary global targets, including that of a 25% relative reduction in p...
This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in
Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe ... in humans and,
although uncommon, it has the potential to cause epidemics with significant case fatality. All recorded MVD
outbreaks to date have originated in Africa. MVD is not an airborne disease and is considered not to be
contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people
and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical
equipment is required for transmission. The risk of infection is minimised when proper infection prevention and
control precautions are strictly followed. There is no approved treatment or vaccine for MVD; however, several
pharmaceuticals and candidate MVD vaccines are under investigation.
